New drug tested for rare vasculitis falls short
NCT ID NCT05376319
First seen May 12, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tested whether a newer drug, obinutuzumab, works better than the standard drug rituximab for a rare disease that causes inflammation of blood vessels (ANCA-associated vasculitis). The goal was to see if patients could achieve remission and clear certain antibodies from their blood. The study was stopped early after enrolling only 6 people, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.